RAB is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). It is also indicated for the maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance).
Mode of Action
RAB suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase at the secretory surface of the gastric parietal cell. It blocks the final step of gastric acid secretion.
Peak plasma concentrations (Cmax) of RAB occur over a range of 2.0 to 5.0 hours (Tmax). Bioavailability: Approximately 52%. High fat meal may delay the absorption up to 4 hours or longer. RAB is 96.3% bound to human plasma proteins. Approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid, its glucuronide, and mercapturic acid metabolites.
Dosage and Recommendation
GERD: 20 mg once daily for 4-8 weeks; or according to the response Gastric Ulcer: 20 mg once daily for 6-12 weeks Duodenal ulcer: 20 mg once daily for 4-8 weeks H-Pylori eradication: 20 mg bid with two antibacterial for a week
Packing and Presentation
Available in 20mg tablet Each strip contains 10 × 10s.